No Data
No Data
Fujia (301371.SZ): The registration inspection of recombinant type III human collagen freeze-dried fiber has been completed, and it is expected to take about one year for the clinical stage.
Fujia (301371.SZ) received specific inquiries on September 9, 2024 regarding the progress of the company's Class III medical instruments. The company stated that the progress of our Class III medical instruments is basically in line with expectations. The recombination III human collagen protein freeze-dried fibers have made rapid progress, and registration and testing have been completed. The next step is the clinical stage, which is expected to take about a year. If the progress goes as expected, this product will be our first Class III medical instrument.
Currently, the company has 4 types of medical instruments products in the category II.
On September 9, Gelunhui reported that Fuljia (301371.SZ) conducted a specific object survey on September 9, 2024, regarding "How many types of Class II medical instruments the company currently sells, and whether there are any product reserves in the future?" The company stated that there are currently 4 types of Class II medical instruments, including: Medical Hyaluronic Acid Sodium Repair Patch (White Film), Medical Hyaluronic Acid Sodium Repair Patch (Black Film), Medical Hyaluronic Acid Sodium Repair Liquid, Medical Recombinant Type III Human Collagen Patch. The company is also developing two more types of Class II medical instruments, namely Medical Seaweed Glucose Repair Patch and Medical Polyglutamic Acid Sodium Repair Patch.
Furunvita (301371.SZ): The online channel revenue in the first half of the year was 0.472 billion yuan, accounting for 50.26%.
On September 9th, Gelonhui reported that Fuerjia (301371.SZ) conducted targeted research on September 9th, 2024 and asked, 'In the future, will the company's sales end be more inclined towards online or offline?' The company stated that in recent years, online revenue has continued to grow, and currently there is still a large online space. The company adopts a deep synergy between online and offline channels in terms of sales channels, and has a sales model that covers direct sales, distribution, and consignment, creating diversified terminal consumer scenarios. The online channel revenue in the first half of this year was 0.472 billion yuan, accounting for 50.26%, and the offline channel revenue was 0.467 billion yuan, accounting for 49.74%.
Shiljia: 2024 Semi-Annual Report
Schierjia: Summary of the 2024 Semi-Annual Report
Fuerjia (301371.SZ): The net income in the first half of the year was 0.34 billion yuan, a year-on-year decrease of 3.71%.
On August 29, Guangdong Hui Rijia (301371.SZ) announced its semi-annual report for 2024. The operating income for the reporting period was 0.94 billion yuan, an increase of 8.17% year-on-year. The net income attributable to the shareholders of the listed company was 0.34 billion yuan, a decrease of 3.71% year-on-year. The net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 0.324 billion yuan, a decrease of 5.47% year-on-year. The basic earnings per share were 0.85 yuan.
No Data
No Data